focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Britain says it expects its vaccine contracts to be met

Fri, 29th Jan 2021 08:23

* UK refuses to publish Astra supply details

* Scotland says it will publish vaccine supply data

* EU warns drug companies over supply delays
(Adds UK PM Johnson's spokesman, Scottish health minister)

By Sarah Young and William James

LONDON, Jan 29 (Reuters) - Britain is confident it will
receive sufficient COVID-19 vaccine doses to keep its programme
on track despite a dispute between the European Union and
drugmaker AstraZeneca, Prime Minister Boris Johnson's spokesman
said on Friday.

EU Commission Head Ursula von der Leyen has demanded that
Astrazeneca deliver contracted vaccine supplies from Britain to
EU states, and has dimissed the notion that the United Kingdom
should have first rights to doses produced there.

The EU has warned drug companies that it would use all legal
means or even block exports unless they agreed to deliver shots
as promised.

The bloc published its contract with AstraZeneca on Friday,
which said the Anglo-Swedish drugmaker should use facilities in
Britain as well as continental Europe in its best efforts to
manufacture its vaccines for the EU.

Prime Minister Boris Johnson's spokesman said on Friday the
government would not discuss contractual matters. But he said
the government expected contracts to be "facilitated" and he was
confident of its supply.

"AstraZeneca has clearly stated they will be able to provide
2 million vaccine doses a week and we've said we will get that
to people as quickly as possible," he said.

While Britain is running ahead of its European peers on
vaccinations, with almost 7.5 million receiving their first dose
so far, the British COVID-19 death toll has surpassed 100,000,
and is the highest in Europe.

A third national lockdown in England is expected to run
until at least March as ministers try to bring a more contagious
variant of the virus under control. Scotland, Wales and Northern
Ireland, whose governments decide on their own measures, are
also living under tight restrictions.

AHEAD ON MANUFACTURING

The swiftest mass vaccination drive in history is stoking
tensions across the world as big powers buy up doses in bulk and
poorer nations try to navigate a financial and diplomatic
minefield to collect whatever supplies are left.

The United Kingdom has secured 367 million doses of the
seven most promising vaccines, including 100 million doses of
the AstraZeneca vaccine which was developed by Oxford
University.

Among those procured by Britain include a vaccine developed
by Novavax, which on Thursday said it proved 89%
effective in a UK trial, and Johnson & Johnson, which on Friday
said its shot was between 72% to 66% effective.

Kate Bingham, the former head of Britain's vaccine
taskforce, said the country had been able to secure supplies by
supporting pharmaceutical companies, setting up clinical trials
quickly and helping firms procure equipment to increase
manufacturing.

She declined to comment on the detail of the contract with
AstraZeneca but said the United Kingdom had benefited from early
work to be ready to make vaccines.

"That is ultimately the difference as to why we're so far
ahead on manufacturing," Bingham said, adding that she did not
expect the EU to block vaccine exports to the United Kingdom.

NO LONGER TENABLE

Scotland will publish COVID-19 detailed vaccine supply data
next week even though the British government has refused to do
so.

British prisons minister Lucy Frazer said the government
could not publish supply details for national security reasons,
which she declined to specify.

Scotland's health minister Jeane Freeman said that citing
national security was "not credible" because the British
government had repeatedly briefed statistics to reporters
showing how much vaccine Scotland had been allocated.

"We've held off publication in the past at their request.
But that's no longer tenable," she said at a news conference.

"The public have a right to clarity and we will give them
that. We're not talking about future supplies, we're talking
about known supplies."
(Reporting by Sarah Young, Alistair Smout and William James;
editing by Angus MacSwan)

More News
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.